Journal of Yeungnam Medical Science

CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study

Byung Woog Kang, Dong Won Baek, Eunhye Chang, Hye Jin Kim, Su Yeon Park, Jun Seok Park, Gyu Seog Choi, Jin Ho Baek, Jong Gwang Kim

J Yeungnam Med Sci. 2022;39(2):141-149. Published online December 22, 2021
DOI: https://doi.org/10.12701/yujm.2021.01571

Clinical implication of adjuvant chemotherapy according to mismatch repair status in patients with intermediate-risk stage II colon cancer: a retrospective study

Byung Woog Kang, Dong Won Baek, Eunhye Chang, Hye Jin Kim, Su Yeon Park, Jun Seok Park, Gyu Seog Choi, Jin Ho Baek, Jong Gwang Kim

Journal of Yeungnam Medical Science. 2022;39(2):141-149

Link1

Link2 Link3

ERCC1, Defective Mismatch Repair Status as Predictive Biomarker of Survival for Stage III Colon Cancer Patients Receiving Oxaliplatin Based Adjuvant Chemotherapy

P. Li, G. Chen

Annals of Oncology. 2012;23:ix180

Link1 Link2

Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer

Kiley W.J. Loh, Michael Michael, John R. Zalcberg, Michael Jefford

Clinical Colorectal Cancer. 2015;14(3):192-197

Link1 Link2

6160 POSTER Impact of Adjuvant Chemotherapy on Survival of Patients With Stage II Colon Cancer – Retrospective Study

E. ElAlfv, Y. El Kerm, A. Kandil, S. Zaky

European Journal of Cancer. 2011;47:S440

Link1 Link2

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy

P Li, Y J Fang, F Li, Q J Ou, G Chen, G Ma

British Journal of Cancer. 2013;108(6):1238-1244

Link1

Link2 Link3

Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer

S.R. Verhoeff, F.N. van Erning, V.E.P.P. Lemmens, J.H.W. de Wilt, J.F.M. Pruijt

International Journal of Cancer. 2016;139(1):187-193

Link1 Link2

Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer

Aalok Kumar, Hagen F. Kennecke, Daniel J. Renouf, Howard J. Lim, Sharlene Gill, Ryan Woods, Caroline Speers, Winson Y. Cheung

Cancer. 2014;121(4):527-534

Link1 Link2

Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer

Leigh Casadaban, Garth Rauscher, Mebea Aklilu, Dana Villenes, Sally Freels, Ajay V. Maker

Cancer. 2016;122(21):3277-3287

Link1 Link2

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair

Huabin Hu, Zehua Wu, Chao Wang, Yan Huang, Jianwei Zhang, Yue Cai, Xiaoyu Xie, Jianxia Li, Cailu Shen, Weiwei Li, Jiayu Ling, Xuehu Xu, Yanhong Deng

Frontiers in Oncology. 2020;10:

Link1

A Combined Analysis of Mismatch Repair Status and Thymidylate Synthase Expression in Stage II and III Colon Cancer

Katarina Öhrling, Mia Karlberg, David Edler, Marja Hallström, Peter Ragnhammar

Clinical Colorectal Cancer. 2013;12(2):128-135

Link1 Link2